VTGN Insider Trading Activity and SEC Form 4 Filings
VTGN insider trading summary
No open-market insider purchases or sales of Vistagen Therapeutics, Inc. (VTGN) have been reported on SEC Form 4 in the past 12 months.
Latest VTGN insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Aug 7, 2023 | Commodore Capital LP | 10% Owner | Buy | $18.0M (775,756 @ $23.15) |
| Aug 18, 2022 | Jerry B Gin | Insider | Buy | $18K (100,000 @ $0.18) |
| Aug 18, 2022 | Jerry B Gin | Insider | Buy | $18K (100,000 @ $0.18) |
| Aug 17, 2022 | Shawn Singh | Chief Executive Officer | Buy | $103K (600,000 @ $0.17) |
| Aug 17, 2022 | Reid G. Adler | Chief Legal Officer | Buy | $51K (300,000 @ $0.17) |
| Jul 12, 2022 | VHCP Co-Investment Holdings III, LLC | 10% Owner | Sell | $53K (60,000 @ $0.89) |
| Jul 12, 2022 | Bong Y Koh | 10% Owner | Sell | $53K (60,000 @ $0.89) |
| Jul 12, 2022 | Venrock Healthcare Capital Partners II, L.P. | 10% Owner | Sell | $53K (60,000 @ $0.89) |
| Jul 12, 2022 | Venrock Healthcare Capital Partners EG, L.P. | 10% Owner | Sell | $53K (60,000 @ $0.89) |
| Jul 12, 2022 | Venrock Healthcare Capital Partners III, L.P. | 10% Owner | Sell | $53K (60,000 @ $0.89) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.